Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Matulane
Procarbazine is an alkylating antineoplastic agent used in the treatment of Hodgkin lymphoma as part of the BEACOPP regimen. It is a prodrug that is metabolized to active metabolites that damage DNA and RNA, thereby inhibiting cell growth and leading to cell death. Procarbazine is classified as a hydrazine derivative.
Used in combination chemotherapy regimens for Hodgkin lymphoma.
Procarbazine has a Black Box Warning for secondary malignancies, pulmonary toxicity, and potential for severe birth defects. It should not be used during pregnancy or breastfeeding.
Outcome:
Disulfiram-like reaction
Mechanism:
Inhibition of acetaldehyde dehydrogenase
Outcome:
Decreased procarbazine efficacy
Mechanism:
Enzyme induction
Outcome:
Decreased procarbazine absorption
Mechanism:
Altered gastric pH
Most likely new formulation: Liposomal procarbazine to reduce toxicity (Year: 2028, 30% confidence)
Based on historical usage patterns and emerging research, there is a low (5%) likelihood of a change in the FDA status of procarbazine in the next 5 years.
Alkylating Agent, Antineoplastic
Hydrazine Derivative